Approximately 25.8 million
Americans have diabetes, according to the National Diabetes Education Program,
making the disease the seventh leading cause of death in the United States. To
put it in monetary perspective, diabetes runs up an annual tab of $174 billion
in total healthcare and related treatment costs.
Boston Therapeutics is
focused on the development and commercialization of novel compounds based on
complex carbohydrate chemistry to address unmet medical needs, including
diabetes. The company’s current product pipeline is comprised of therapies
developed to treat patient populations with Type 2 diabetes, which accounts for
90-95 percent of all diagnosed cases of diabetes in adults.
PAZ320 is Boston
Therapeutics’ chewable drug candidate designed to prevent diabetes and its
complications. The company believes PAZ320 is a safe and effective drug
compound for people with pre-diabetes and diabetes in their daily management of
blood glucose levels, fulfilling an unmet medical need of increasing
proportion. In its phase 2 clinical trial, 45 percent of the patients saw a 40
percent reduction in the elevation of post meal blood sugar compared to
baseline.
IPOXYN, a universal oxygen
carrier, is Boston Therapeutics’ injectable drug candidate for the prevention
of necrosis (premature cell death following ischemia) and ischemic conditions,
which are caused by the shortage of oxygen supply to the tissue due to
restriction in blood supply. Necrosis is the outcome of severe and acute
injury, involved in many pathological conditions, including diabetes. For now,
the only treatment for necrosis is providing oxygen by a high pressure facility,
creating a crucial need to develop drugs for prevention and treatment of this
pathology.
Supported by a highly
dedicated management and advisory team with extensive expertise in complex
carbohydrate chemistry, regulatory affairs, and clinical development, Boston
Therapeutics is well-positioned to advance position as a high-potential
developer of complex carbohydrate-based new chemical entities for the treatment
of diabetes.
For more information, visit
www.bostonti.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
